![]() |
RGNX | Regenxbio Inc. |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 2.45 |
Leverage | 44.23% |
Market Cap | $ 324.3m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -157.1m |
Margin | -100.63% |
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.